Faron plans €40m rights issue to fund bexmarilimab through key cancer trial milestones

Faron Pharmaceuticals Oy ( (GB:FARN) ) just unveiled an announcement.

Faron Pharmaceuticals plans to launch a rights offering of approximately EUR 40 million, giving existing shareholders pre-emptive subscription rights to fund the next stage of clinical development for its lead cancer drug bexmarilimab. The board argues that equity financing via a rights issue is the most suitable option to strengthen the balance sheet, align shareholder interests, and support long-term value creation, pending approval at an Extraordinary General Meeting on 2 March 2026.

Proceeds are earmarked primarily for the Phase II portion of an FDA-agreed Phase II/III trial of bexmarilimab plus azacitidine in frontline high-risk myelodysplastic syndrome, as well as several investigator-initiated studies across multiple cancers. By aligning its clinical endpoints with new FDA MDS guidelines and exploiting gaps created by competitors’ failures, Faron aims to shorten trial timelines, control costs, and enhance the commercial appeal of bexmarilimab, potentially strengthening its position in the oncology landscape and its prospects for future partnerships.

More about Faron Pharmaceuticals Oy

Faron Pharmaceuticals is a Finnish clinical-stage biopharmaceutical company focused on developing novel immuno-oncology therapies. Its lead asset, bexmarilimab, is being advanced for high-risk myelodysplastic syndrome and multiple solid tumors, with a strategy aimed at securing regulatory approvals and potential commercial partnerships in major cancer markets.

See more data about FARN stock on TipRanks’ Stock Analysis page.